Anti-STXBP1 Monoclonal Antibody for WB, IHC-P, ELISA - P61764

Core Product Specifications and Parameters

Biological Background: STXBP1 Function and Localization

• STXBP1 (Syntaxin-binding protein 1), also known as MUNC18-1/N-Sec1/unc-18 homolog 1, is a crucial regulator of synaptic vesicle exocytosis and neurotransmitter release.
• It binds syntaxin-1 (STX1A) in a 1:1 ratio and mediates SNARE complex assembly at presynaptic membranes, essential for vesicle docking and fusion.
• STXBP1 can also interact with syntaxins 2 and 3, but not syntaxin 4, suggesting a role in determining intracellular fusion specificity.
• Localized predominantly in the cytoplasm and membrane, with enrichment in neuronal axons and high expression in brain and spinal cord.
• The protein is subject to alternative splicing and phosphorylation, and mutations are associated with developmental and epileptic encephalopathies (DEE4) and intellectual disability.
• UniProt keywords include 3D-structure, alternative splicing, disease variant, epilepsy, intellectual disability, phosphoprotein, and protein transport.

Experimental Guidance and Technical Tips

• The immunogen corresponds to a synthetic peptide within residues 400–500 of human STXBP1; verify that this sequence is conserved in your species of interest for optimal cross-reactivity.
• For WB, a band at approximately 68 kDa is expected; consider using appropriate loading controls and validate with tissue or cell lysates known to express STXBP1.
• For IHC-P, antigen retrieval conditions may require optimization; positive control tissues include human or rodent brain sections.
• ELISA protocols can be developed using the antibody as a capture or detection reagent; pair with a suitable secondary antibody and validate with recombinant STXBP1 protein.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio provides diagnostic manufacturers, CROs, and research institutions with streamlined access to high-quality IVD raw materials. This STXBP1 antibody supports neuroscience and synaptic disorder research, and we can supply validated antibody pairs, bulk monoclonal/polyclonal reagents, and ancillary raw materials. Let us help you source rare targets and accelerate your assay development from concept to clinic.